UPS

UPS outperformed the broader market on October 20, 2026, rising 1.09% to $98.52, ahead of the S&P 500's 0.28% gain. The stock has gained 2.86% over the past month, leading its Transportation sector.

Ahead of earnings on October 27, analysts expect EPS of $1.63 (down 6.32% YoY) and quarterly revenue of $22.23 billion (up 3.8% YoY). UPS carries a Zacks Rank #3 (Hold) with a Forward P/E of 13.56, trading at a discount to its industry average of 15.56.

UPS's dividend will likely survive through 2027 but remains under pressure. The company froze its dividend earlier this year and is allocating nearly all free cash flow to maintain the payout.

With declining free cash flow projections ($5.47B in 2025 to $5.01B in 2027) and a 98% payout ratio, dividend safety is questionable despite competitive pressures that may prevent a cut. The stock's 6.7% yield doesn't compensate for the risks, and investors may find safer alternatives in the industrial sector.

The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, expanding at a CAGR of 8.4%. Growth is driven by rising R&D investments, increasing chronic disease prevalence, and demand for specialized logistics for biologics, personalized medicine, and decentralized trials. Key players include Thermo Fisher Scientific, Catalent, Almac Group, and UPS Healthcare.